---
layout: post
title: "Competitive Generic Therapies; Guidance for Industry; Availability"
date: 2026-02-05 19:08:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-05293
original_published: 2020-03-16 00:00:00 +0000
significance: 8.00
---

# Competitive Generic Therapies; Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 16, 2020 00:00 UTC
**Document Number:** 2020-05293

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Competitive Generic Therapies." This guidance provides a description of the process that applicants should follow to request designation of a drug as a competitive generic therapy (CGT) and the criteria for designating a drug as a CGT. In addition, this guidance includes information on the actions that FDA may take to expedite the development and review of an abbreviated new drug application (ANDA) for a drug designated as a CGT. Further, this guidance provides information on how FDA implements the statutory provision for a 180-day exclusivity period for certain first approved applicants that submit ANDAs for drugs designated as a CGT. This guidance finalizes the draft guidance of the same title dated February 19, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/03/16/2020-05293/competitive-generic-therapies-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2020-05293

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
